Background: Evolving epidemiological data and increasing antibiotic resistance mandate an update of the European and North American Societies of Pediatric Gastroenterology, Hepatology and Nutrition guidelines.

Methods: Certainty of evidence and strength of recommendations were rated by experts according to the Grading of Recommendation Assessment, Development, and Evaluation approach. PICO (patient population, intervention, comparator, and outcome) questions were developed and voted on by the group. Recommendations were formulated using the Evidence to Decision framework.

Results: The current literature supports many of the previous recommendations and several new recommendations. Invasive testing with strain antimicrobial susceptibility analysis is recommended for the diagnosis and selection of eradication therapy for H. pylori infection. Molecular methods are acceptable for detection of infection and of antibiotic resistance in gastric biopsy specimens. Reliable, noninvasive tests can be used as a screening method for children with history of gastric cancer in a first-degree relative. When investigating causes of chronic immune thrombocytopenic purpura, testing for H. pylori is no longer recommended. When investigating other diseases such as inflammatory bowel disease, celiac disease, or eosinophilic esophagitis, specific diagnostic biopsies for H. pylori infection are not indicated. However, if H. pylori is an incidental finding, treatment may be considered after discussing the risks and benefits. Treatment should be based on antibiotic antimicrobial susceptibility testing and, if unavailable, regimens containing clarithromycin should be avoided.

Conclusions: Due to decreasing prevalence of infection, increasing challenges with antibiotic resistance, and emerging evidence regarding complications of infection, clinicians must be aware of these recommended changes to appropriately manage H. pylori infection and its clinical sequelae in children.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jpn3.12314DOI Listing

Publication Analysis

Top Keywords

pylori infection
16
antibiotic resistance
12
antimicrobial susceptibility
8
infection
7
pylori
6
updated joint
4
joint espghan/naspghan
4
espghan/naspghan guidelines
4
guidelines management
4
management helicobacter
4

Similar Publications

Helicobacter pylori and its role in the pathogenesis of follicular gastritis: an overview.

Rev Gastroenterol Peru

January 2025

Infectious Diseases and Cancer Research Group, Centro de Investigaciones Clinicas, Fundacion Hospital San Pedro, Pasto, Nariño, Colombia; Colombian Research Group on Helicobacter pylori, Bogota D.C., Colombia.

The role of Helicobacter pylori in the pathogenesis of peptic ulcers and gastric adenocarcinoma is widely known; however, it is not entirely understood how bacterial infection is closely related to the genesis of follicular gastritis and some types of gastric lymphoma. Diagnosing and pathogenic mechanisms follicular gastritis remain challenging. Therefore, this article aims to examine the role of H.

View Article and Find Full Text PDF

[An update of the Helicobacter pylori treatment: a Latin American Gastric Cancer, Helicobacter and Microbiota Study Group review].

Rev Gastroenterol Peru

January 2025

Departamento de Gastroenterología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.

Helicobacter pylori (H. pylori) is the primary etiological agent of gastric adenocarcinoma, which affects over 60% of the global population, with a significant prevalence in Latin America. Given its impact on the affected population, it is crucial to understand the diagnostic tools available for detecting this infection.

View Article and Find Full Text PDF

[Treatment of Helicobacter pylori infection in the era of antibiotic resistance. What do we know?].

Rev Gastroenterol Peru

January 2024

Unidad Motilidad Digestiva, Clínica San Felipe, Lima, Perú; Servicio de Gastroenterología Clínica Ricardo Palma, Lima, Perú; Universidad Peruana Cayetano Heredia, Lima, Perú.

View Article and Find Full Text PDF

Background: Helicobacter pylori (H. pylori), a specific bacterium capable of surviving in the acidic environment of the stomach, has been recognized as a group of causative agents of gastric cancer. Therefore, the development of mucosal vaccines against H.

View Article and Find Full Text PDF

Background & Aims: Screening for, and treating, Helicobacter pylori (H. pylori) in the general population or patients with early gastric neoplasia could reduce incidence of, and mortality from, gastric cancer. We updated a meta-analysis of randomized controlled trials (RCTs) examining this issue.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!